VV169 / Vyriad - LARVOL DELTA

Lead in vivo CAR T candidate VV169 (Businesswire) - "100% of mice treated with a single intravenous injection of therapy cleared OPM-2 tumors completely within 28 days. This response held true for all dose levels, including the lowest dose tested. The mice remained tumor-free 84 days post-treatment and successfully resisted tumor re-challenge; The treatment was well tolerated. Analysis of cytokines confirmed the absence of a severe cytokine storm. While IFNγ was elevated during T-cell expansion, inflammatory markers, such as IL-6, TNFα and GM-CSF, were barely detectable....Vyriad is continuing preclinical work for the development of VV169 and plans to begin a clinical trial in the U.S. in 2026."

New trial • Preclinical • Multiple Myeloma